ICON Plc (ICLR):企業の財務・戦略的SWOT分析

◆英語タイトル:ICON Plc (ICLR) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH8733FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年3月
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥56,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

ICON Plc (ICLR) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ICON plc (ICON) is a contract research organization (CRO) that provides outsourced development services to the biotechnology, pharmaceutical and medical device industries worldwide. It provides specialized services that span the entire lifecycle of product development. The company’s service portfolio includes adaptive trials, biosimilars, clinical research services, commercialization and outcomes, consulting, functional services provision, medical imaging, laboratory services, resourcing solutions and strategic support and tactical solutions for traditional, in vitro diagnostic and software devices. The company offers research services in areas of cancer, genomics, central nervous system, cardiovascular, endocrine and metabolic disorders, gastrointestinal, medical device, nonalcoholic steatohepatitis (NASH), ophthalmology, rare and orphan diseases, transplant and immunology, vaccines and women’s health therapeutics areas among others. ICON is headquartered in Dublin, Ireland.

ICON Plc Key Recent Developments

Feb 24,2021: Ireland’s ICON signs agreement to acquire PRA Health Sciences
Oct 21,2020: Icon reports third quarter 2020 results
Oct 19,2020: BARDA reselects ICON as preferred partner to help strengthen US emergency preparedness and response
Oct 07,2020: ICON wins best CRO at the vaccine industry excellence wwards
Sep 03,2020: ICON launches Accellacare a global clinical research network focused on increasing patient recruitment with a patient centric approach

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
ICON Plc – Key Facts
ICON Plc – Key Employees
ICON Plc – Key Employee Biographies
ICON Plc – Major Products and Services
ICON Plc – History
ICON Plc – Company Statement
ICON Plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
ICON Plc – Business Description
Geographical Segment: Ireland
Performance
Geographical Segment: Other
Performance
Geographical Segment: Rest of Europe
Performance
Geographical Segment: US
Performance
ICON Plc – Corporate Strategy
ICON Plc – SWOT Analysis
SWOT Analysis – Overview
ICON Plc – Strengths
ICON Plc – Weaknesses
ICON Plc – Opportunities
ICON Plc – Threats
ICON Plc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
ICON Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
ICON Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
ICON Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Oct 21, 2020: Icon reports third quarter 2020 results
Oct 19, 2020: BARDA reselects ICON as preferred partner to help strengthen US emergency preparedness and response
Oct 07, 2020: ICON wins best CRO at the vaccine industry excellence wwards
Sep 03, 2020: ICON launches Accellacare a global clinical research network focused on increasing patient recruitment with a patient centric approach
Jul 22, 2020: ICON reports second qquarter 2020 results
May 05, 2020: ICON appoints new Chief Medical Officer
Apr 22, 2020: ICON reports first quarter 2020 results
Apr 09, 2020: ICON wins multiple categories in 2020 CRO Leadership Awards third year in a row
Apr 03, 2020: ICON signs new service agreement with Pfizer
Mar 23, 2020: ICON launches the coronavirus observatory
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
ICON Plc, Key Facts
ICON Plc, Key Employees
ICON Plc, Key Employee Biographies
ICON Plc, Major Products and Services
ICON Plc, History
ICON Plc, Subsidiaries
ICON Plc, Key Competitors
ICON Plc, Ratios based on current share price
ICON Plc, Annual Ratios
ICON Plc, Annual Ratios (Cont...1)
ICON Plc, Annual Ratios (Cont...2)
ICON Plc, Interim Ratios
ICON Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
ICON Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
ICON Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[ICON Plc (ICLR):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Boiron SA:企業の戦略・SWOT・財務分析
    Boiron SA - Strategy, SWOT and Corporate Finance Report Summary Boiron SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • AMEWAS, Inc.:企業の戦略・SWOT・財務分析
    AMEWAS, Inc. - Strategy, SWOT and Corporate Finance Report Summary AMEWAS, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Quanta Services Inc (PWR):企業の財務・戦略的SWOT分析
    Quanta Services Inc (PWR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Providence Resources plc (PZQA):企業の財務・戦略的SWOT分析
    Summary Providence Resources Plc (Providence Resource) is an upstream oil and gas exploration and development company that explores and develops hydrocarbon assets. The company's areas of operations include Northern Porcupine basin, Southern Porcupine basin, Goban Spur basin, Saint George's basin an …
  • Bioneer Corp (064550):製薬・医療:M&Aディール及び事業提携情報
    Summary Bioneer Corp (Bioneer) is a molecular diagnostic company that develops and produces molecular research and molecular diagnostic products and instruments. The company’s major molecular research products include DNA/RNA amplification pre mixes, DNA/RNA preparation system, oligo synthesis and r …
  • Beautiful Brands International, LLC:企業の戦略・SWOT・財務分析
    Beautiful Brands International, LLC - Strategy, SWOT and Corporate Finance Report Summary Beautiful Brands International, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Cancer Genetics Inc (CGIX):企業の財務・戦略的SWOT分析
    Summary Cancer Genetics Inc (CGI) is a pharmaceutical company that offers diagnostic products and services enabling precision medicine in the field of oncology. It offers products such as CGH microarrays, next-generation sequencing and DNA-FISH Probes. The company's oncology tests and laboratory ser …
  • Arsenal Holdings plc:企業の戦略的SWOT分析
    Arsenal Holdings plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • The Lubrizol Corp:企業の戦略的SWOT分析
    The Lubrizol Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Cellectis SA (ALCLS):企業の財務・戦略的SWOT分析
    Summary Cellectis SA (Cellectis) operates as a clinical-stage biopharmaceutical company. It carries out research, develop and commercialize gene editing technology. The company pioneers gene editing company, deploying core proprietary technologies to develop off-the-shelf immunotherapies to target a …
  • Shanghai Pharmaceutical Co Ltd (601607):医療機器:M&Aディール及び事業提携情報
    Summary Shanghai Pharmaceutical Co Ltd (Shanghai Pharma) is a manufacturer, retailer, wholesaler and distributor of healthcare products. The company carries out the research and development, manufacture and sale of pharmaceutical products for treating HER2 positive advanced breast cancer, systemic a …
  • Seventh Sense Biosystems Inc-医療機器分野:企業M&A・提携分析
    Summary Seventh Sense Biosystems Inc (Seventh Sense) is a medical device company that develops and markets blood collection devices. The company’s products comprise testing devices, TAP devices, sterile and microneedle arrays among others. It uses TAP Touch Activated Phlebotomy painless blood collec …
  • Senhwa Biosciences Inc (6492):製薬・医療:M&Aディール及び事業提携情報
    Summary Senhwa Biosciences Inc (Senhwa) is a clinical stage drug development company that develops next generation DNA damage response drugs for the treatment of cancer. The company’s pipeline products include CX-5461 and CX-4945. Its CX-5461, a G4-stabilizing compound, is a Pol I inhibitor that tri …
  • Acome:企業の戦略・SWOT・財務情報
    Acome - Strategy, SWOT and Corporate Finance Report Summary Acome - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, provid …
  • Synthetic Biologics Inc (SYN):企業の財務・戦略的SWOT分析
    Summary Synthetic Biologics Inc (Synthetic Biologics), formerly Adeona Pharmaceuticals Inc is a clinical company that develops novel therapeutics to treat gut microbiome. The company’s pipeline products include SYN-004 and SYN-010. Its SYN-010 is a proprietary, modified-release formulation which is …
  • Innovative Targeting Solutions Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Innovative Targeting Solutions Inc (ITS) is an antibody generation company that discovers and develops novel human monoclonal antibody technologies. The company develops a next generation protein engineering platform that helps for the generation of fully human antibody and T cell receptor b …
  • Indian Oil Corporation Limited:企業の戦略・SWOT・財務分析
    Indian Oil Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Indian Oil Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Arvinas Inc (ARVN):製薬・医療:M&Aディール及び事業提携情報
    Summary Arvinas Inc (Arvinas) is a biopharmaceutical company that develops protein degradation therapeutics. The company develops novel therapeutics for the treatment of pro-inflammatory, cancer, autoimmune and rare diseases. Its proprietary approach is to target disease causing proteins. Arvinas’s …
  • Offshore Marine Management Limited:企業の戦略的SWOT分析
    Offshore Marine Management Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Advaxis Inc (ADXS):企業の財務・戦略的SWOT分析
    Advaxis Inc (ADXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆